Notable Labs Ltd 's ability to collect accounts receivable sequentially worsen to 2.26, indicating more challenging environment then in the first quarter 2024, but still, it is a far cry from any concerns. Notable Labs Ltd 's Accounts Receivable average collection period in the Jun 30 2024 quarter, has increased to 162 days, from 108 days, in the Mar 31 2024 quarter.

If we take a look into Healthcare sector Notable Labs Ltd achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Notable Labs Ltd Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NTBL Receivables Turnover Ratio	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter
Y / Y Receivable Change	-	-	2225 %	-	-
Y / Y Revenue Change	-	-	-	-	-
Receivable Turnover Ratio (TTM)	2.26	3.37	6.67	-	240.5
NTBL's Total Ranking	#	#	#	#	#
Accounts Receivable average collection period days	161	108	55	-	2
Seq. Receivable Change	0.55 %	-1.61 %	-	-	-
Seq. Revenue Change	100 %	-99.68 %	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Receivable Turnover Ratio Statistics
High	Average	Low
0	0	0

NTBL Company Profile • Back to NTBL Efficiency Comparisons • Compare NTBL Receivables Turnover Ratio to its Competitors

Financial Statements
Notable Labs Ltd 's Accounts Receivable	$ 0 Millions	Visit NTBL's Balance sheet
Notable Labs Ltd 's Sales TTM	$ 0 Millions	Visit NTBL's Income Statement
Sources of NTBL's Revenues		Visit NTBL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NTBL's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NTBL's Growth Rates	NTBL's Roa	NTBL's Inventory Turnover Ratio	NTBL's Dividend Comparisons
NTBL's Profitability Ratios	NTBL's Roi	NTBL's Asset Turnover Ratio	NTBL's Dividend Growth
NTBL's Valuation Ratios	NTBL's Roe	NTBL's Financial Strength Ratios	NTBL's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2024, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2024	Receivable at quarter ending Jun 30 2024
Sight Sciences Inc	4.68	$ 78.078 Millions	$ 16.693 Millions
Anaptysbio Inc	4.65	$ 30.473 Millions	$ 6.554 Millions
Sonoma Pharmaceuticals Inc	4.64	$ 12.699 Millions	$ 2.735 Millions
Orthopediatrics Corp	4.62	$ 174.079 Millions	$ 37.642 Millions
Adaptive Biotechnologies Corporation	4.60	$ 168.766 Millions	$ 36.703 Millions
Opus Genetics Inc	4.59	$ 16.449 Millions	$ 3.585 Millions
Lantheus Holdings Inc	4.59	$ 1,436.679 Millions	$ 313.292 Millions
Cryoport inc	4.59	$ 190.417 Millions	$ 41.528 Millions
Intra cellular Therapies Inc	4.58	$ 564.526 Millions	$ 123.390 Millions
Mirum Pharmaceuticals Inc	4.57	$ 264.376 Millions	$ 57.808 Millions
Amgen Inc	4.56	$ 30,934.000 Millions	$ 6,780.750 Millions
Kewaunee Scientific Corporation	4.55	$ 201.625 Millions	$ 44.323 Millions
Pro dex Inc	4.54	$ 53.844 Millions	$ 11.847 Millions
Harrow Inc	4.51	$ 152.987 Millions	$ 33.919 Millions
Bionano Genomics Inc	4.49	$ 36.579 Millions	$ 8.139 Millions
Liquidia Corporation	4.49	$ 14.840 Millions	$ 3.305 Millions
Alkermes Plc	4.46	$ 1,507.916 Millions	$ 338.109 Millions
Emmaus Life Sciences Inc	4.44	$ 19.626 Millions	$ 4.425 Millions
Xeris Biopharma Holdings Inc	4.40	$ 181.413 Millions	$ 41.254 Millions
Xencor Inc	4.39	$ 150.034 Millions	$ 34.211 Millions
Neuronetics Inc	4.38	$ 71.658 Millions	$ 16.363 Millions
Vericel Corporation	4.38	$ 214.520 Millions	$ 49.004 Millions
Karyopharm Therapeutics Inc	4.35	$ 145.668 Millions	$ 33.491 Millions
C4 Therapeutics Inc	4.34	$ 29.378 Millions	$ 6.766 Millions
Healthcare Services Group Inc	4.33	$ 1,684.949 Millions	$ 389.335 Millions
Whitehawk Therapeutics Inc	4.32	$ 23.817 Millions	$ 5.515 Millions
Bristol myers Squibb Company	4.32	$ 46,509.000 Millions	$ 10,773.750 Millions
Bioventus Inc	4.31	$ 537.170 Millions	$ 124.634 Millions
Eli Lilly And Company	4.30	$ 38,922.800 Millions	$ 9,042.775 Millions
Supernus Pharmaceuticals inc	4.30	$ 630.163 Millions	$ 146.537 Millions

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.